降压药物相关基因多态性在某院高血压患者中的应用研究

目的 分析来我院就诊高血压患者中降压药物相关基因型的频率分布，为高血压患者个体化治疗提供参考和临床依据。方法 收集2021年6月—2022年4月在中国人民解放军总医院海南医院就诊的高血压患者，共72例。采用PCR-熔解曲线法检测CYP2D6*10(c.100 C>T)、CYP2C9*3(c.1075 A>C)、ADRB1(c.1165 G>C)、AGTR1(c.1166 A>C)、ACE(I/D)、NPPA(T2238C)和CYP3A5*3(A6986G)，并分析不同基因型与生化指标的关系。结果 对72例患者各位点基因及基因型频率进行统计，7个位点基因频率均符合Hardy-Weinberg平衡。ADRB1基因型存在性别差异(χ²=5.878, P<0.05)。AGTR1位点不同基因型的患者之间三酰甘油[AA:1.4(1.0, 2.0)mmol/L;AC:2.2(1.5, 2.5)mmol/L;P=0.038]、总胆固醇[AA:4.0(3.1, 4.9)mmol/L;AC:4.8(4.0, 5.3)mmol/L;P=0.040]、低密度...

Antihypertensive drug-related genes polymorphisms in hypertensive patients at a certain hospital

Objective By analyzing the frequency distribution of antihypertensive drug-related genotypes in hypertensionpatients treated in our hospital, so as to provide a clinical basis for individualized treatment of hypertension patients. Methods A total of 72 hypertensive patients treated in Hainan Hospital of PLA General Hospital from June 2021 to April 2022 were collected. PCR-melting curve method was used to detect CYP2D6^*10 (c.100 C>T), CYP2C9^*3 (c.1075 A>C), ADRB1 (c.1165 G>C), AGTR1 (c.1166 A>C), ACE (I/D), NPPA (T2238C) and CYP3A5^*3 (A6986G), and the relationship between different genotypes and biochemical indexes was analyzed. Results According to the statistics of the gene and genotype frequency of each point in 72 patients, the gene frequencies of 7 sites all conformed to Hardy Weinberg equilibrium. There were gender differences in ADRB1 genotypes (χ² = 5.878, P<0.05). There were statistical differences in triglycerides [AA: 1.4 (1.0, 2.0)mmol/L; AC: 2.2 (1.5, 2.5)mmol/L; P=0.038], total cholesterol [AA: 4.0 (3.1, 4.9) mmol/L; AC: 4.8 (4.0, 5.3) mmol/L; P=0.040] and low-density lipoprotein cholesterol [(AA: 2.4 (1.8, 3.3) mmol/L; AC: 3.2 (2.5, 3.5) mmol/L; P=0.035] among patients with different genotypes of AGTR1 locus. The patients with different genotypes of CYP2C9 locus had significant differences in their alanine transferase (ALT) [AA:16.9 (11.4,30.2) mmol/L; AC:10.4 (9.4, 18.2) mmol/L; P=0.040]. Aftergene-directed individualized therapy, different genotypes of CYP3A5 andAGTR1 affected the heart rate [CYP3A5: AA: (79.3±7.0) beats/min; AG (69.8±6.8) beats/min; GG (68.8±7.3) beats/min; P=0.010], systolic blood pressure [AGTR1: AA: (131.3±16.7) mmHg; AC: (140.6±11.8) mmHg; P=0.014] and diastolic blood pressure [CYP3A5: AA: (90.0±8.3) mmHg; AG: (78.7±10.8) mmHg; GG: (74.9±10.7) mmHg; P=0.025; AGTR1: AA: (75.3±10.2) mmHg; AC: (86.3±10.6) mmHg; P=0.001] of patients. Conclusions The related gene loci of antihypertensive drugs are an important basis for guiding the diversification and individualization of clinical medication. Clinicians need to consider the impact of related genes on drug efficacy and adverse reactions when prescribing.